Risk sharing: Pharma's failure to prove its value
This article was originally published in Scrip
Executive Summary
Risk sharing deals are popular in the UK and now in the US, but some government bodies view them as a way for companies to establish higher prices elsewhere. Francesca Bruce, Scrip's Europe reporter, discovers that they may not be a viable business model.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.